Home > Boards > US Listed > Biotechs > Chembio Diagnostics (CEMI)

Glancy Prongay & Murray Reminds Investors of Looming

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Doug M Member Profile
 
Followed By 7
Posts 453
Boards Moderated 0
Alias Born 08/26/08
160x600 placeholder
Chembio Diagnostics Announces CE Mark for DPP SARS-CoV-2 Antigen and IgM/IgG Test Systems GlobeNewswire Inc. - 1/14/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/18/2020 9:24:22 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 12/18/2020 9:22:35 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/17/2020 5:15:40 PM
Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors GlobeNewswire Inc. - 12/17/2020 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/4/2020 6:05:19 AM
Chembio Diagnostics Awarded $12.7 Million by BARDA for Development of Rapid DPP Respiratory Antigen Panel and 510(k) Submissi... GlobeNewswire Inc. - 12/2/2020 1:22:29 PM
Chembio Diagnostics Receives ANVISA Approval for DPP SARS-CoV-2 Antigen Test System in Brazil GlobeNewswire Inc. - 11/13/2020 4:40:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2020 5:11:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2020 4:17:04 PM
Chembio Diagnostics Reports Third Quarter 2020 Financial Results GlobeNewswire Inc. - 11/5/2020 4:05:00 PM
Chembio Diagnostics to Report Third Quarter 2020 Financial Results on November 5, 2020 GlobeNewswire Inc. - 10/23/2020 8:00:10 AM
Chembio Diagnostics Submits EUA Application for DPP SARS-CoV-2 Antigen Test System GlobeNewswire Inc. - 10/15/2020 5:55:10 PM
Chembio Diagnostics Receives FDA Approval for DPP HIV-Syphilis System GlobeNewswire Inc. - 10/2/2020 7:26:09 AM
Chembio Submits EUA Application for New DPP SARS-CoV-2 IgM/IgG Test System GlobeNewswire Inc. - 9/8/2020 6:01:08 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2020 7:43:29 AM
Chembio Diagnostics Reports Second Quarter 2020 Financial Results GlobeNewswire Inc. - 8/6/2020 4:05:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 7:19:40 AM
Chembio Diagnostics to Report Second Quarter 2020 Financial Results on August 6, 2020 GlobeNewswire Inc. - 7/23/2020 4:10:10 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 7/8/2020 10:00:37 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/8/2020 9:43:40 AM
Chembio Diagnostics Announces Preliminary Estimates of Second Quarter 2020 Revenues GlobeNewswire Inc. - 7/6/2020 4:23:03 PM
Chembio Announces Plans to Seek EUA Approval from FDA for Revised DPP COVID-19 IgM/IgG System and New DPP COVID-19 Antigen Sy... GlobeNewswire Inc. - 7/6/2020 4:11:10 PM
Chembio Diagnostics Awarded BARDA Contract for Development of DPP COVID-19 Point-of-Care Antigen System GlobeNewswire Inc. - 7/6/2020 4:10:10 PM
Chembio to Report COVID-19 Product Development Plans and Preliminary Estimated Second Quarter 2020 Revenue Results GlobeNewswire Inc. - 7/1/2020 5:00:10 PM
Doug M   Friday, 07/31/20 03:10:07 PM
Re: None
Post # of 455 
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Chembio Diagnostics, Inc. (CEMI)
12:00pm ET 7/31/2020 Globe Newswire

Mentioned in article
CEMI
Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ: CEMI) common stock between March 12, 2020 and June 16, 2020, inclusive (the "Class Period").

If you suffered a loss on your Chembio investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/chembio-diagnostics-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

In April 2020, the Company's COVID-19 antibody test was one of the first to be granted Emergency Use Authorization ("EUA") by the U.S. Food and Drug Administration ("FDA").

Then, on June 17, 2020, before the market opened, the FDA revoked the EUA for Chembio's Dual Path Platform COVID-19 serology test due to concerns regarding the test's accuracy. Specifically, the FDA found that the "benefits no longer outweigh its risks" and that "it is not reasonable to believe that the test may be effective" because it "generates a higher than expected rate of false results and higher than that reflected in the authorized labeling for the device."

On this news, the Company's share price fell $6.04, or nearly 60%, to close at $3.89 per share on June 17, 2020.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Chembio common stock during the Class Period, you may move the Court no later than August 17, 2020 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles

Charles Linehan, 310-201-9150 or 888-773-9224

shareholders@glancylaw.com

www.glancylaw.com

https://ml.globenewswire.com/media/dca1d463-f40e-41ea-a1d6-f8a47b633445/small/gpm-logo-jpg.jpg

comtex tracking

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences